Facebook
Twitter
LinkedIn
ForwardCase-Based Insights on Hematologic Malignancies
Overview
The Case-Based Insights on Hematologic Malignancies Conference is a CME-accredited, in-person hematology conference featuring leading hematology experts. Expert faculty will place recent updates into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists/Oncologists
- Oncology Nurse Practitioners
- Oncology Pharmacists
- Oncology Physician Assistants
- Oncology Fellows/Residents
- Oncology Nurses
- Researchers and others involved in the care of cancer patients
Organizing Committee
Conference Director:
- Dr. Binay Shah - Binaytara
Conference Chair:
- Dr. Muhamed Baljevic - Vanderbilt University Medical Center
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review recent updates & discuss their applications in clinical settings.
- Choose new therapeutic options for treating benign and malignant hematologic disorders, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and hematology patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
Program
Saturday, May 3, 2025
All times are listed in Central Daylight Time (CDT)
08:00 AM – 09:00 AM Registration, Breakfast, & Exhibits
09:00 AM – 09:05 AM Welcome
09:05 AM – 09:20 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
09:20 AM – 10:45 AM Session 1 - Multiple Myeloma
Session Chair: Muhamed Baljevic, MD, FACP
09:20 AM – 09:45 AM Management approaches in HR smoldering MM, TE NDMM and TIE NDMM - Noura Elsedawy, MD
09:45 AM – 10:00 AM Treating early and late RRMM – navigating most optimal sequencing of therapies - Jesus Berdeja, MD
10:00 AM – 10:15 AM Q & A with Case-Based Discussion 1 – How to use MRD in MM? - Kian Rahbari MD
10:15 AM – 10:30 AM Q & A with Case-Based Discussion 2 – When to CAR and when to BiTE in RRMM - Eden A. Biltibo MD
10:30 AM – 10:45 AM Q & A with Case-Based Discussion 3 – Preventing and managing early and late TCR toxicities in MM - Katheryn Kennedy, APP
10:45 AM – 11:00 AM Break & Exhibits
11:00 AM – 12:25 PM Session 2 - Lymphomas
Session Chair: David Morgan, MD
11:00 AM – 11:20 AM Choosing among CAR T therapies in LBLC - Andrew P. Jallouk , MD, PhD
11:20 AM – 11:40 AM Autologous Transplant and CAR-T in MCL - Vivek Patel MD
11:40 AM – 11:55 AM Q & A with Case-Based Discussion 1 – Role of CAR-T Cell Therapy in CLL - Megan Wanca, APP
11:55 AM – 12:10 PM Q & A with Case-Based Discussion 2 – Navigating evolving Bispecific Antibody Landscape in NHL- Jarrod Smith, MD
12:10 PM – 12:25 PM Q & A with Case-Based Discussion 3 – Updates in the management of HL- Shakhti Baskar, MD
12:25 PM – 1:25 PM Lunch & Exhibits
01:25 PM – 01:45 PM Keynote: Rouge blood: somatic clones, inflammation, and hematopoietic malignancies - Michael R. Savona, MD
01:45 PM – 03:10 PM Session 3 - Acute Leukemias, MPN, MDS, CHIP/CCUS
Session Chair: Michael R. Savona, MD
01:45 PM – 02:05 PM Evolving approaches in newly diagnosed AML - Stephen Strickland, MD, MSCI
02:05 PM – 02:25 PM Therapeutic updates in the management of myelofibrosis - Ashwin Kishtagari, MD
02:25 PM – 02:40 PM Q & A with Case-Based Discussion 1 – Treatment Landscape in MDS - Swapna Thota, MD
02:40 PM – 02:55 PM Q & A with Case-Based Discussion 2 – Updates in the treatment of Adult ALL - Michael T. Byrne, D.O.
02:55 PM – 03:10 PM Q & A with Case-Based Discussion 3 – New Therapeutic developments for MPNs - Sanjay R. Mohan, MD
03:10 PM – 03:30 PM Break & Exhibits
03:30 PM – 05:05 PM Session 4 - Special Issues in Cellular and TCR Therapies
Session Chair: Bipin N. Savani, MD
03:30 PM – 03:50 PM Outpatient Delivery Of CAR T-cell Therapy - Minoo Battiwalla, MD, MS
03:50 PM – 04:10 PM Outpatient delivery of bispecific antibodies in hematologic malignancies: past, present and future - Sarah Profitt, PharmD
04:10 PM – 04:30 PM Q & A with Case-Based Discussion 1 – Contemporary updates in the prevention and management of graft-versus-host disease - Adetola Kassim, MD, MS
04:30 PM – 04:50 PM Q & A with Case-Based Discussion 2 –Long term complications after haplo SCT - Bipin N. Savani, MD
04:50 PM – 05:05 PM Q & A with Case-Based Discussion 3 – Planning TCR Therapy in VA patients - Salyka Sengsayadeth, MD
05:05 PM Adjourn
Venue
Parking
Reduced Event Only Valet parking rate of $15.00 per vehicle (plus applicable taxes).
Faculty
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Muhamed Baljevic, MD, FACP
MINOCHER BATTIWALLA, MD
Jesus Berdeja
Andrew Jallouk
Ashwin Kishtagari
Vivek Patel
Sarah Profitt, PharmD, BCOP
Stephen Strickland, MD, MSCI
Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP®
Swapna Thota
Accreditation
Available Credit
- 5.75 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 5.75 ACPE Pharmacy
The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-014-L01-P
Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.
The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
- 5.75 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 5.75 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Exhibitors
If you are interested in exhibiting at this meeting or purchasing a badge with your company at our discounted rate for exhibitors, please visit our exhibit page here - https://www.sponsorships.binayfoundation.org/NashvilleCellular
Register/Take course
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.